Preventing Chaos: The Critical Role of the Submission Lead

Authors

  • Anjana Bose, PhD Certara, Inc, Radnor, PA
  • Mark Bowlby, PhD Certara, Inc, Radnor, PA
  • Brenda Taylor, MS, CAPM Certara, Inc, Radnor, PA
  • Steve Sibley, MS Certara, Inc, Radnor, PA

DOI:

https://doi.org/10.55752/amwa.2024.315

Abstract

Pharmaceutical product marketing applications represent the end result of years of development, significant financial investment, months of work, and the collaboration of a very large cross-functional team. Clearly, the Submission Lead for any marketing application team is a critical role. Experienced regulatory/medical writers often have the necessary array of skills to make excellent Submission Leads, whether they are overseeing only the writing activities or leading the entire submission team.

The Submission Lead serves as the “connector” by providing strategic and tactical oversight throughout the process to ensure on-time preparation of high-quality documents. By enabling the work in each stage of the submission, from initial regulatory submission strategy through publishing and submission, the Submission Lead ensures the development of a comprehensive and cohesive marketing application. Submission Leads wear many hats and ensure that the team is functioning well and communicating at all times. Teams benefit from a Submission Lead with extensive marketing application experience because they are better able to mitigate the challenges and risks that arise.

Submission Leads fluent in the strategy and content of the submission are able to drive discussions and prioritize team activities. Most importantly, as the project progresses, this strategy and content knowledge allows the Submission Lead to recognize potential cross functional impacts of each new development and to ensure the necessary parties are brought together to address those impacts. Like any large team effort, a clearly defined lead role and agreed processes are critical to achieve a high-quality, on-time marketing application that is accepted for review and ultimately results in regulatory approval.

Author Biographies

Anjana Bose, PhD, Certara, Inc, Radnor, PA

Anjana Bose, PhD, Director, Global Submissions

Dr. Bose has over 30 years of experience in the pharmaceutical industry, including leadership roles in regulatory submissions, clinical development, and data analytics. During the last 15 years, she has led many successful New Drug Applications and Biologic License Applications to the United States (US) Food and Drug Administration, provided strategic input in planning submissions in the electronic Common Technical Document (eCTD) structure, and authored labeling and Module 2 summary documents. Dr. Bose’s areas of concentration are in rare diseases, oncology, multiple sclerosis, psychiatry, and neurology. Dr. Bose has collaborated with multiple partner companies in Europe in preparation of briefing books and integrated summary documents and has participated in many meetings with regulatory agencies in and outside of the US. Dr. Bose also has collaborated with Medical Affairs and Commercial Teams in preparation of posters, presentations, and manuscripts.

Mark Bowlby, PhD, Certara, Inc, Radnor, PA

Mark R. Bowlby, PhD, Senior Director, Global Submissions

Dr. Bowlby has over 27 years of experience in the clinical research and drug development industry. During the last 12 years, he has led many New Drug Applications, Biologics License Applications, and Investigational New Drug (IND) submissions to the Food and Drug Administration and European Medicines Agency. Dr. Bowlby has led the authoring of labeling, Module 2 clinical summaries and overviews, briefing packages, investigator’s brochures (IBs), as well as study-level regulatory documents. Earlier in his career, Dr. Bowlby planned and wrote numerous biomedical manuscripts, posters, and slides regarding his scientific research and postdoctoral work at Harvard Medical School. His therapeutic areas of expertise include chronic kidney diseases, ophthalmology, movement disorders, cardiac arrythmias, neurology, psychiatry, and chronic pain. He has an expert understanding of drug discovery and development approaches used in the current biopharmaceutical environment.

Brenda Taylor, MS, CAPM, Certara, Inc, Radnor, PA

Brenda Taylor, MS, CAPM, Director, Global Submissions

Mrs. Taylor has over 20 years of experience in the biotechnology and pharmaceutical industry. She has led regulatory strategy and submission management activities to support pharmaceutical development and manufacturing, with an emphasis on Initial New Drug (IND) applications and marketing applications. Brenda’s research background in microbiology and immunology includes design and performance of nonclinical studies. Her therapeutic areas of expertise include oncology, cardiovascular, and anti-infective agents, spanning both small‑molecule drugs and biologics.

Published

2024-06-13

How to Cite

1.
Bose A, Bowlby M, Taylor B, Sibley S. Preventing Chaos: The Critical Role of the Submission Lead. AMWA. 2024;39(2). doi:10.55752/amwa.2024.315

Issue

Section

Topical Features